Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Drug Profile

Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Alternative Names: AFM 12; AFM 18; AFM 20; AFM 21; AFM 22; AFM 24; AFM 24+; AFM 26; AFM 26+; AMV-564; anti CD19 x anti CD16; anti CD33 X anti CD3; anti-EGFRvIII/CD16A Tand AB; anti-EGFRvIII/CD3 TandAb; anti-EpCAM TandAb; Antibody-based non-Hodgkin's lymphoma therapeutics - Affimed; MHC-peptide complex antibody - Affimed; T-564; Trispecific Abs

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Amphivena Therapeutics
  • Class Bispecific antibodies; Monoclonal antibodies; Trispecific antibodies
  • Mechanism of Action Apoptosis stimulants; B-cell maturation antigen modulators; CD19 antigen modulators; CD200 antigen modulators; CD3 antigen modulators; CD33 antigen modulators; Epidermal growth factor receptor antagonists; Epithelial cell adhesion molecule inhibitors; Fc gamma receptor IIIA modulators; Immunomodulators; Major histocompatibility complex inhibitors; Natural killer cell stimulants; T lymphocyte stimulants; T-lymphocyte differentiation antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 01 Mar 2017 Preclinical data for AFM 24 and AFM 26 in Cancer released by Affimed
  • 03 Nov 2016 Preclinical trials in Cancer in Germany (Parenteral)
  • 03 Nov 2016 Amphivena Therapeutics plans a phase I trial for AMV 564 for Acute myeloid leukaemia in
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top